Details
Stereochemistry | RACEMIC |
Molecular Formula | C14H19NO2.ClH |
Molecular Weight | 269.767 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.C(C1COC2=C(O1)C=CC=C2)N3CCCCC3
InChI
InChIKey=BITRJBQGQMGGQI-UHFFFAOYSA-N
InChI=1S/C14H19NO2.ClH/c1-4-8-15(9-5-1)10-12-11-16-13-6-2-3-7-14(13)17-12;/h2-3,6-7,12H,1,4-5,8-11H2;1H
Molecular Formula | C14H19NO2 |
Molecular Weight | 233.3062 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Piperoxan is the first antihistamine was discovered. Piperoxan protected guinea pigs against histamine-induced bronchospasm. The piperoxan has been used to provoke anxiety behaviors in the monkey. Piperoxan is an alpha-adrenergic antagonist. Piperoxan has been claimed to preferentially block presynaptic alpha-adrenoreceptors leading to an increase in noradrenaline release and by this way the postsynaptic alpha-adrenoreceptors blockade may be overcome. There was clear evidence that piperoxan enhanced myocardial performance. Piperoxan is a diagnostic aid used in studies of hypertension.
Approval Year
Doses
Dose | Population | Adverse events |
---|---|---|
10 mg single, intravenous Recommended Dose: 10 mg Route: intravenous Route: single Dose: 10 mg Sources: |
unhealthy, adult n = 1 Health Status: unhealthy Condition: overdose of adrenaline (5 mg) Age Group: adult Sex: unknown Population Size: 1 Sources: |
|
15 mg single, intravenous Recommended Dose: 15 mg Route: intravenous Route: single Dose: 15 mg Sources: |
unhealthy, adult n = 62 Health Status: unhealthy Condition: hypertension Age Group: adult Sex: unknown Population Size: 62 Sources: |
Other AEs: Pulse rapid... |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Pulse rapid | 16 patients | 15 mg single, intravenous Recommended Dose: 15 mg Route: intravenous Route: single Dose: 15 mg Sources: |
unhealthy, adult n = 62 Health Status: unhealthy Condition: hypertension Age Group: adult Sex: unknown Population Size: 62 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Differentiation of drugs acting centrally upon the cardiovascular system by means of sympathetic and vagal responses. | 1978 |
|
Pharmacological characteristics of spinal alpha-adrenoreceptors in rats. | 1981 Mar |
|
Role of alpha-2 adrenergic receptors in anti-ulcer effect mechanism of estrogen and luteinising hormone on rats. | 2009 Apr |
Patents
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 18:56:59 GMT 2023
by
admin
on
Fri Dec 15 18:56:59 GMT 2023
|
Record UNII |
KS0DZ1UQNW
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29713
Created by
admin on Fri Dec 15 18:56:59 GMT 2023 , Edited by admin on Fri Dec 15 18:56:59 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
101619
Created by
admin on Fri Dec 15 18:56:59 GMT 2023 , Edited by admin on Fri Dec 15 18:56:59 GMT 2023
|
PRIMARY | |||
|
DTXSID00928851
Created by
admin on Fri Dec 15 18:56:59 GMT 2023 , Edited by admin on Fri Dec 15 18:56:59 GMT 2023
|
PRIMARY | |||
|
6211-27-4
Created by
admin on Fri Dec 15 18:56:59 GMT 2023 , Edited by admin on Fri Dec 15 18:56:59 GMT 2023
|
SUPERSEDED | |||
|
135-87-5
Created by
admin on Fri Dec 15 18:56:59 GMT 2023 , Edited by admin on Fri Dec 15 18:56:59 GMT 2023
|
PRIMARY | |||
|
KS0DZ1UQNW
Created by
admin on Fri Dec 15 18:56:59 GMT 2023 , Edited by admin on Fri Dec 15 18:56:59 GMT 2023
|
PRIMARY | |||
|
C81370
Created by
admin on Fri Dec 15 18:56:59 GMT 2023 , Edited by admin on Fri Dec 15 18:56:59 GMT 2023
|
PRIMARY | |||
|
205-222-3
Created by
admin on Fri Dec 15 18:56:59 GMT 2023 , Edited by admin on Fri Dec 15 18:56:59 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |